AbbVie announced that the European Commission has approved Skyrizi for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- ABBV Earnings: AbbVie Exceeds Q2 Expectations Driven by Strong Immunology Sales
- AbbVie Reports Second-Quarter 2024 Financial Results
- Options Volatility and Implied Earnings Moves Today, July 25, 2024
- Notable companies reporting before tomorrow’s open
- Frontier Medicines announces milestone payment in AbbVie partnership